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Abstract
Objective: The MicroMed DeBakey left ventricular assist device (LVAD) axial blood flow pump was used as bridge to heart
transplantation (HTx) in patients with terminal heart failure. The aim was to evaluate this novel mechanical circulatory support system in
regard to overall outcome. Methods: Prospective study in 15 HTx candidates (mean age 40 ^ 7 years) with terminal heart failure and
maximal medical treatment due to ischemic cardiomyopathy (CMP, n ¼ 5), dilated CMP ðn ¼ 3Þ, restrictive CMP ðn ¼ 2Þ, unclassified CMP
ðn ¼ 1Þ, metabolic CMP ðn ¼ 1Þ, valvular CMP ðn ¼ 1Þ and congenital CMP ðn ¼ 2Þ. All patients were implanted with a MicroMed
DeBakey LVAD. A rescue procedure was necessary in eight critical patients, while seven underwent elective LVAD implantation.
Procedures were performed via median sternotomy, in normotherm femoro-femoral CPB (mean duration 59 ^ 1 min). Oral Marcoumarq
(INR 2.0–3.0) and Aspirinq (100 mg daily) were started as soon as possible. Patients were discharged into a specialized rehabilitation clinic
from which it was possible to release them home after a few weeks. Results: Successful implantation and discharge from ICU (mean stay
10 ^ 7 days) was possible in 11 patients. Seven were transplanted (mean support 50.7 days) and one is awaiting HTx (support.310 days) in
the comfort of his home (NYHA I). Survival was 100% among the transplanted patients. Of the seven elective implants, five, and of the eight
rescue procedures three patients underwent successful HTx. Four patients died early, while three patients died late on pump support due to
intracranial hemorrhage (n ¼ 2, 73 and 76 days) and chest infection (n ¼ 1, 124 days). All survivors were discharged from hospital, with
significant decrease in NYHA class (mean 3.8–2.4 ðn ¼ 11Þ). Treadmill testing showed increased exercise tolerance, from 35 to 71 W
ðn ¼ 4Þ. Plasma BNP values (mean 950–162 ng/l ðn ¼ 4Þ) and pulmonary resistance (mean 316–194.5 dyne s/cm5 ðn ¼ 3Þ) decreased
significantly during LVAD support. Conclusions: The MicroMed DeBakey LVAD is simple to implant; outpatient treatment is safe and
efficient. Patients’ condition and pulmonary resistances normalize within 6 weeks, making previously considered inoperable patients
amenable for HTx. HTx can be performed in low-risk situation, allowing better donor–recipient matching and improving overall outcome.
q 2003 Elsevier Science B.V. All rights reserved.
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1. Introduction
The incidence of chronic heart failure (CHF) is
increasing due to the aging population and its improved
medical management. With disease progression to terminal
heart failure, therapeutic options become fewer and cardiac
transplantation (HTx) presents itself as the last option. HTx
is also one of the most limited therapies, not only in regard
to the lack of donor hearts (,3000 HTx performed each year
worldwide) but also due to the surgical limitations inherent
to the clinical aspects of this severely ill patient population.
Mechanical circulatory support systems have been deve-
loped as effective adjuvant therapeutic options in these
terminally ill patients. Since the creation of the artificial
heart program by the national institute of health (NIH) [1] in
1964, numerous different mechanical circulatory support
systems have been elaborated upon. Copeland and associ-
ates [2] performed the first bridging to HTx by mechanical
support in 1985. Mortality of terminal heart failure being
very high as disease progresses, HTx candidates die while
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waiting on long lists [3,4]. According to the recently
published REMATCH study [3], the use of left ventricular
assist devices (LVAD) resulted in more than twice the
survival rate and an improved quality of life, in comparison
to optimal medical management. Researchers from the
Baylor College of Medicine (Houston, TX) with engineers
from NASA have been developing the DeBakey LVAD
produced by MicroMed Inc. since 1988 [5]. This implan-
table continuous axial flow pump creates a maximal flow in
excess 10 l/min, hence providing relief to the sick heart by
taking over part of the pumping action [6]. As the DeBakey
LVAD has been available at our center since October 1999,
we evaluated this new device in 15 consecutive patients and
report our results in regard to overall outcome in HTx
candidates.
2. Materials and methods
From October 1999 until December 2002, 15 patients
(mean age 40 ^ 17 years, one female, 14 male) have been
implanted with a MicroMed DeBakey LVAD (MicroMed
Inc, Houston, TX, USA). To qualify, patients had to fulfill
institutional inclusion criteria for terminal heart failure
(Table 1). All patients were accepted on the transplantation
list and gave their informed consent as stated by our local
ethics committee, when this was not possible their legal
representative did so. Patient’s medical history and
indication for LVAD implantation are resumed in Tables
2 and 3. A precise description of the DeBakey LVAD was
done previously by Noon et al. [5,7].
2.1. Implant procedure
After general anesthesia and median sternotomy, the
pericardium was opened, diaphragmatic attachment to the
costal margin divided and both extended laterally beyond
the apex. Patients were systemically heparinized (Heparinw
100 IE/kg) in preparation for heparinized normotherm CPB
with femoro-femoral veno-arterial cannulation. The left
ventricular apex was elevated; the insertion site of the
inflow cannula selected and an apical fixation ring sewn to
the apex. In preparation for insertion of the pump inflow
cannula, the heart remained beating in the last five cases, in
ventricular fibrillation in the ones prior. A round bladed
coring device was used to create a hole in the left ventricular
apex permitting insertion of the inflow cannula. The apical
insertion site was carefully checked for bleeding, and
Flowsealw was applied to the sutures holding the inflow
tract in place to insure perfect hemostasis. Then tunneling
was performed in order to exit through the skin in a
convenient position above the iliac crest. The pump was
placed into the abdominal pocket and the length of the
outflow graft measured and trimmed. A lateral anastomosis
to the ascending aorta was done so as to protect the outflow
graft from injury during HTx surgery. After completion of
the anastomosis and de-airing of the system, pumping was
started at 7500 rpm and adjusted to maintain a cardiac index
.2.0 l/min/m2. Pump output was gradually increased, to
unload the heart, while catecholamines were started to
increase output. Protaminew was given to reverse heparin
(ratio 1:1). Hemostasis and anticoagulation were conducted
with a modified Szefner protocol [8].
2.2. Post-operative management
Anticoagulation was started with intravenous heparin
early post-operative (6–8 h, PTT aim .60 s) with Anti-
thrombine III substitution when ,80%. Antivitamin K
(Marcoumarw) and Aspirinw were initiated as soon as pos-
sible (target international normalized ratio (INR) 2.0–3.0).
When anticoagulation was insufficient, low weight heparin
(Fragminw 2500IE s.c. 1 or 2 £ daily) was added. Anti-
coagulation was monitored in the ICU every 4 h, daily on
the regular ward (twice daily when abnormal) and on
ambulation at least three times per week, of which once
in our clinic.
After implanting and adjusting of coagulation para-
meters, the manning of the pump required limited special
training. Nurses and patients were informed about practical
functions of the external pump controller device and the
patients were trained to deal with alarms when on leave
from the hospital. Patients were also instructed on how to
take care of the exit site wound, and were able to change
their bandages themselves. The display screen of the
controller device allowed patients to check their pump
data themselves. This datum was collected on provided
pump data sheets.
As soon as the patients were ambulating, they were
released into a specialized cardiovascular rehabilitation
clinic or went directly home, returning to our clinic once
a week for a full check-up by a multidisciplinary LVAD
team (cardiologist and surgeon).
3. Results
3.1. Surgery
Surgery was performed by the same senior surgeon with
Table 1
Inclusion criteria
†Left atrial or pulmonary capillary wedge pressure .18 mmHg
†Mean arterial pressure ,90 mmHg
†Cardiac index ,2.0 l/min/m2
†Left ventricular ejection fraction ,25%
†Incomplete response to intravenous drugs
†Intraaortic balloon pump support (IABP)
or: At high-risk of sudden cardiac arrest
And: accepted by Transplantation Committee for HTx
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a mean duration of 256 ^ 4 min, cardiopulmonary bypass
(CPB) was 69 ^ 1 min with no surgical complications
occurring. Fourteen patients were weaned from CPB in the
operating room; one was operated under extra corporal
membranous oxygenation (ECMO) support. After a mean
stay in the ICU of 10 ^ 7 days, 11 patients returned to the
regular ward. Total mean support duration on the device was
64 ^ 61 days. No device related events occurred in 956
patients support days. Six patients were able to be released
into a selected rehabilitation facility.
3.2. Clinical outcome
Table 4 resumes complications and outcome. To date,
seven patients have been successfully bridged to HTx (mean
support 54 ^ 22 days). Survival after HTx after a mean
follow up of 27 ^ 10 months is 100%. One patient is still
awaiting a suitable donor organ on LVAD support (.310
support days) discharged from the hospital.
In the presented series, four early deaths occurred during
the ICU stay. Three patients died late: two patients suffering
fatal hemorrhagic strokes (days 73 and 76) and one patient
developing a central graft infection (Germ: Staphylococcus
coagulase negative) leading to MOF (day 124).
3.3. Clinical data
Clinical improvement was seen in all survivors, as
testified by the decrease in NYHA classification (mean
3.8–2.4, n ¼ 11). Plasma BNP values as markers of CHF
normalized within 6 weeks (from mean 950 to 162 ng/l,
n ¼ 9). In regard to right ventricular hemodynamics, pre-
and post-operative invasive cardiac monitoring was rou-
tinely performed in the last four elective patients of this
series. This showed a significant decrease of pulmonary
vascular resistance (PVR) (from mean 316 to
194.5 dyne s/cm5) over the whole LVAD support period.
The increase in exercise tolerance was reported by the
patients themselves and documented by treadmill ergometry
(from mean 35 to 71 W) in six. Cardiac echocardiography
showed increased contractility with significant flow through
the aortic valve and increased left ventricular ejection
fraction in all patients.
End organ perfusion normalized under LVAD support in
Table 2
Pre-operative patient demographics
Patient 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15
Age 18 47 53 48 51 17 14 55 41 18 37 52 64 61 18
Sex M M M F M M M M M M M M M M M
Height 168 169 171 172 187 169 178 186 176 185 186 182 185 170 152
Weight 49 76 71 67 80 50 60 61 72 94 92 92 64 68 52
HR 96 84 96 100 120 115 96 100 80 88 90 95 88 84 92
BP 98/68 84/52 70/50 105/75 100/50 110/57 96/54 130/75 100/54 95/50 90/60 85/50 80/50 85/65 78/62
GCS 15 15 15 15 10 8 15 10 15 14 15 15 15 15 7
NYHA IV IV IV III IV IV IV IV IV IV III III III III IV
CI 1,5 1,8 n.a. n.a. n.a. n.a. 1,9 1,4 n.a. n.a. 1.9 n.a. n.a. 1.5 1.2
Other Iono IABP IABP, Iono Iono IABP, Iono ECMO ECMO
BP, blood pressure (mmHg); HR, heart rate (bpm); GCS, Glasgow coma scale; NYHA, New York Heart Association; CI, cardiac index (l/min/m2); IABP,
intraaortic balloon pump; Iono, intravenous inotrop support; ECMO, extra corporal membranous oxygenation; M, male; F, female.
Table 3
Indication for LVAD implantation and disease history
Patient 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15
Disease DIL DIL ISC RES NC CONG MET ISC ISC CONG ISC ISC VLV DIL RES
Nicotine No Yes No No Yes No No Yes No No Yes Yes Yes Yes No
DM No Yes No No No No No No No No Yes No No No No
HR R AR R R R AR AR AR R R R AR AR R AR
Prev. surg. No Yes No No No Yesa No Yesb No Yesc Yesb No Yesd No Yes
Surg. U U E E U U U U E U E E E E U
Other K.B. GI MI £ 2 Amyl ARCA ARCA x Stroke Cor Cor x x x x X
Prev. surg, previous surgery; DIL, dilatative cardiomyopathy (CMP); CONG, congenital CMP; VLV, valvular CMP; MET, metabolic CMP; GI,
gastrointestinal bleeding; MI, myocardial infarcts; Cor, coronary disease; K.B., Kiener–Becker muscle dystrophy; ARCA, cardiac arrest 24 h prior; D.Sy.,
Danon syndrome; Amyl., severe cardiopulmonary amyloidosis; DM, diabetes mellitus; CM, cardiomyopathy; E, elective implantation; U, urgent/rescue
procedure; RES, restrictive CMP; NC, not classified CMP, X.
a Blalock Shunt.
b CABG, coronary aortic bypass graft.
c Atrial inversion by senning.
d Aortic valve 1987, PM DDD 2000.
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all patients (Figs. 1 and 2). Only two patients developed
significant organ failure: one during massive liver dysfunc-
tion following acute right heart failure (day 7) and one other
developed acute renal failure following a renal infarct,
resolving spontaneously.
No infections at the exit site of the power cables appeared
in any patients.
Four patients showed biological signs of hemolysis, one
developed a fatal stroke (day 73), the second a pericardial
bleeding requiring surgical drainage and two others were
managed by decreasing the pump revolutions per minute
(rpm). Fig. 3 shows hemolysis parameters in 11 patients
over a period of 4 weeks after implantation.
4. Discussion
The evermore present organ shortage for HTx leads to an
increasing necessity of therapeutic options for patients with
terminal heart failure. Several other studies have concluded
that LVAD support is an excellent tool as bridge to
transplant [9,10]. As shown by the REMATCH study [3],
the role of LVAD support is not only limited as bridge to
HTx but destination therapy presents itself as a promising
option. The increasing demand for LVAD support has lead
to the development of different systems with the main
difference being their flow characteristics (pulsatile vs.
continuous). Bleeding and thromboemboli are present with
any kind of disease progression in terminal heart failure
(natural course, LVAD support, total artificial heart). The
main complication of mechanical circulatory support in
these patients is bleeding. As seen with other systems the
DeBakey LVAD comes with a high incidence of bleeding
[4,9], our results indicate no significant differences with
previously reported figures [11].
Survival of HTx after bridging was 100% in our series.
Table 4
Complications and outcome
Patient Type of surgery Minor events Major events Outcome
1 U Hemolysis None HTX on day 60
2 U UTI, renal infarct Stroke Death on day 73
3 E GI bleeding None HTX on day 32
4 E Hemolysis Iatrogenous bleedinga HTX on day 81
5 U Reintubation None HTX on day 80
6 U None Right ventricular failure Death on day 7
7 U Reintubation Massive chest infectionb Death on day 124
8 U None MOF Death on day 16
9 E None Cardiac Tamponadeb HTX on day 25
10 U None None HTX on day 58
11 E Renal insufficiency None HTX on day 42
12 E None None Awaiting transplant, .220 support days
13 E None Ventricular fibrillation, stroke Death on day 76
14 E None Diffuse severe bleeding Death on day 26
15 U None MOF Death on day 6
E, elective implant; U, urgent/rescue procedure; UTI, urinary tract infection; GI, gastrointestinal; MOF, multiorgan failure.
a Due to pleura punction requiring surgery.
b Requiring surgery.
Fig. 1. Liver function (n ¼ 11, mean values).
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None of the bridged patients was unsuitable for HTx after
LVAD support. In total, seven patients died on LVAD
support; one in MOF (day 16), one following a massive
chest infection (day 124), one during emergency redo-
surgery after which it was impossible to wean him from
CPB due to acute right heart failure (day 7), one other never
recuperated from pre-operative MOF (day 6), both these
patients were on ECMO support prior to device implan-
tation. Of the three late deaths, two patients developed
major hemorrhagic strokes (day 73 and 76) while one other
patient died following severe diffuse non-controllable post-
operative bleeding (day 26).
The high overall mortality of 46% ðn ¼ 7Þ can be related
to the following factor: eight emergency implantations were
performed in critical patients. Of these eight patients, three
were successfully bridged to HTx and are doing well to date.
In the group of seven elective implants, mortality was low
considering the bad general state of terminal heart failure
patients.
These results show the importance of the timing of
implantation. As seen in other series, elective implant and
clinical status both determine positive outcome [12]. It is
our belief that early referral and elective implant bring a
higher benefit to this patient population. The three early
deaths in the group of emergency implants can clearly
be attributed to the poor clinical state prior to implant
(Table 4).
The MicroMed DeBakey LVAD is a non-pulsatile
assistance for the left heart, in the early support periods
flows are continuous, but with myocardial recuperation
pulsatility returns. Through the active continuous unloading
of the left ventricle and the aspiration created by the inflow
cannula, the trans-pulmonary gradient is increased. It is
observed that pulmonary wedge pressures are decreased and
increased right heart output is achieved. In comparison to
pulsatile assist devices, the continuous flow created by the
DeBakey LVAD does not depend on native cardiac ejection.
Even with constant rpm, the flow through the LVAD
increases with patients exercise and physical activity.
In one patient who survived 7 h of ventricular fibrillation
before returning to our clinic (recorded by his pace-maker,
most likely cause being hypokaliemia), we documented
absence of heart output by echocardiography. This patient
survived solely by the force of the DeBakey LVAD until he
could be electroconverted (case report in press).
The results of this study indicate that non-pulsatile flow
allows for continuous reduction of post-capillary load
inducing normalization of PVR in patients otherwise not
considered as HTx candidates [7,13].
As seen in other studies, quality of life is improved and
Fig. 2. Kidney function (n ¼ 11, mean values).
Fig. 3. Parameters of hemolysis (n ¼ 11, mean values).
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patients increase their exercise capacities and oxygen
uptake [13]. Moreover the personal discipline necessary
for the management of the LVAD can increase patient’s
medical compliance in the post-HTX phase [14].
Sustained outpatient treatment is straightforward with
this device. The only settings which can vary on the
MicroMed DeBakey LVAD are the rpm of the impeller
pump, these can only be changed on the clinical data
acquiring system (CDASw) in our institution. It appeared
that the rpm and subsequent flow provided by the LVAD
could constantly be reduced with increased support
duration. Fig. 4 shows the trend observed in eight survivors
over 9 weeks, the constant decrease of rpm not only reflects
underlying myocardial recuperation, but also the good
tolerance of this continuous flow hemodynamic support.
This study shows promising results, as the device is
reliable and poses no difficulties to implant and explant
during HTx surgery. By achieving increased end organ
perfusion, organ recuperation as a consequence contributes
in creating a low-risk environment for HTx. Donor–
recipient matches can be more precise, thanks to the
comfort of hemodynamic stability of patients on LVAD
support.
Following the analysis of our data, negative predictive
factors regarding final outcome are: pre-implant ionotropic
cardiovascular support, IABP and general clinical status. As
always in surgical specialties, patient selection determines
overall outcome. Most importantly in our opinion is timing
of implantation.
The precise effect on the brain blood barrier and throm-
bocyte function of intravenous heparin, oral anticoagulation
and continuous flow seem to be an important aspect of
continuous flow LVAD support needing to be further
assessed in the future as duration of support will increase.
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